A Case-Based Clinical Approach to the Investigation, Management and Screening of Families with BRCA2 Related Prostate Cancer by King, B et al.
R E V I E W
A Case-Based Clinical Approach to the 
Investigation, Management and Screening of 




1Institute of Medical and Biomedical 
Education, St. George’s, University of 
London, London, UK; 2Department of 
Oncogenomics, Institute of Cancer 
Research, London, UK; 3Department of 
Clinical Genetics, St George’s University 
Hospitals NHS Foundation Trust, 
London, UK 
Abstract: BRCA2 is the most commonly implicated DNA damage repair gene associated 
with inherited prostate cancer. BRCA2 deficient prostate cancer typically presents at 
a younger age, is more poorly differentiated, and is associated with worse survival outcomes 
than non-BRCA2 associated prostate cancer. Despite these unfavourable prognostic implica-
tions, poly-ADP ribose polymerase inhibitors and platinum-based chemotherapy have been 
identified as potent targeted therapeutic agents towards BRCA1/2 deficient cancer cells. This 
review article explores the literature surrounding BRCA2-related prostate cancer through 
a familial clinical scenario. The investigation, diagnosis and management of BRCA2 deficient 
prostate cancer will be explored, alongside the implications of the identification of a germline 
pathogenic BRCA2 variant within a family, cascade screening and prostate cancer surveil-
lance in unaffected male BRCA2 carriers. A greater understanding of the molecular patho-
genesis of DNA damage repair gene deficient prostate cancer, coupled with new treatment 
paradigms and widened access to both somatic and germline genetic analysis for prostate 
cancer patients and their families will hopefully enable the robust implementation of high 
quality evidence-based clinical pathways for both the management and identification of 
BRCA2 deficient prostate cancer and improved screening, early detection and prevention 
strategies for individuals at increased genetic risk of prostate cancer. 
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Introduction
Prostate cancer (PC) is the most common cancer in males in the UK and remains one 
of the leading causes of morbidity and mortality within the cancer patient population, 
with approximately 1.4 million new diagnoses and around 375,000 associated deaths 
globally in 2020.1 The majority of PC occurs sporadically in males over the age of 
65. These cancers are driven by tumour-specific genetic changes that drive oncogen-
esis (somatic pathogenic variants). Twin studies in Scandinavia have suggested that 
just over half of predisposition to PC may be due to genetic factors.2 Currently, the 
majority of these are common variants contributing to polygenic inheritance, where 
multiple genetic loci associated with a low-moderate risk increase an individual’s 
lifetime risk of developing PC. A smaller proportion of cases are due to single 
moderate-high risk genetic variants.3 These are primarily pathogenic variants in 
DNA damage repair (DDR) genes.
Common variants predisposing to PC are predominantly identified through 
large-scale Genome Wide Association Studies (GWAS), and over 160 single 
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nucleotide polymorphisms (SNPs) associated with PC 
have been identified.4 Whilst individually these SNPs are 
low risk (relative risk ~1.1–1.3), their use in combined 
polygenic risk scores is likely to facilitate future identifi-
cation of more men at risk of PC in clinical practice and 
they have given significant insights into the biological 
pathways and networks underlying oncogenesis.4,5
DNA sequencing of germline DNA in patients with PC 
is the mainstay of identification of rarer moderate-high 
penetrance monogenic variants predisposing to PC. In the 
main, these genes act within DNA damage repair path-
ways and include BRCA1, BRCA2, ATM, PALB2, HOXB13 
as well as mismatch repair genes indicated in Lynch 
Syndrome, particularly MSH2.6–10 Germline variants in 
BRCA2 have been implicated in the pathogenesis of 
1–2% of PCs and have been reported to confer an 
increased relative risk of approximately 2.4–8.6-fold in 
men below the age of 65 years, making it the most com-
monly implicated DDR gene associated with inherited 
PC.3,11–13 BRCA2 germline variants confer a 20% lifetime 
risk of developing PC and are associated with not only 
early-onset disease, but also a worse prognosis than non- 
carriers of BRCA2 germline variants.3,6,7,11,14–18
The BRCA2 gene, located on chromosome 13q12.3, is 
tumour suppressor gene that follows an autosomal domi-
nant pattern of inheritance. BRCA2 encodes for a protein 
which helps to repair double-stranded DNA (dsDNA) 
breaks through homologous recombination (HR) repair. 
Most BRCA2 pathogenic variants are protein truncating 
variants leading to the formation of a truncated, non- 
functional protein. BRCA2 deficient PC in most cases, 
occurs due to biallelic loss of the BRCA2 gene within 
the tumour (loss of both copies of the BRCA2 gene). This 
can occur in the tumour alone or can be due to the 
inheritance of a germline monoallelic pathogenic variant, 
with loss of the second allele within the tumour in accor-
dance with Knudson’s two-hit hypothesis. Therefore, men 
with inherited BRCA2 variants have a higher propensity 
for developing PC if the one remaining unaffected 
BRCA2 allele develops a second single somatic patho-
genic variant leading to oncogenesis.7,19 There are rare 
exceptions, where the mutant allele only is lost in 
a tumour, leaving the normal copy implying that in 
some cases a haplo-insufficiency mechanism leads to 
tumour development.20
In this review article, we will consider BRCA2-related 
PC, considering a hypothetical family (Figure 1) and dis-
cuss the investigation, diagnosis and management of 
BRCA2 deficient PC, alongside the implications of the 
identification of a germline pathogenic variant in the 
BRCA2 gene within a family and PC surveillance in unaf-
fected male BRCA2 carriers. This clinical case-based 
approach is intended to summarise the implications of 
a diagnosis of BRCA2 deficient prostate cancer for both 
the proband and wider family and is complementary to 
more comprehensive systematic reviews21–27providing 
more in depth scientific review on the diagnosis and man-
agement of DDR gene deficient prostate cancer.
Identification and Management of 
BRCA2 Deficient Prostate Cancer
The proband in Figure 1 has just been diagnosed with PC at 
a relatively young age. There are fortunately a number of 
different treatment options for PC which range from con-
servative management with active surveillance to radical 
medical and/or surgical options. The selection of an appro-
priate clinical treatment plan is dependent on a number of 
factors which include (but are not limited to) pre-existing 
patient risk factors, tumour grading and staging, life- 
expectancy and patient preference. Mainstay treatment 
options for low-high risk localised PC include active sur-
veillance, radical prostatectomy, radiotherapy (external 
Figure 1 Pedigree of a hypothetical family carrying a pathogenic BRCA2 germline 
variant. Proband (indicated by red arrow) was diagnosed with PC at 54 years, 
proband’s sister was diagnosed with BC at 41 years and proband’s mother 
(deceased) was diagnosed with OC at 59 years. A maternal uncle (deceased) was 
diagnosed with PC at 61 years. Circles indicate females, squares indicate males. 
A line through a figure indicates that individual is deceased. 
Abbreviations: PC, prostate cancer; BC, breast cancer; OC, ovarian cancer; Dx, 
diagnosis.
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beam or brachytherapy) and androgen-deprivation therapy, 
and high intensity focused ultrasound.11,28,29
Compared to BRCA proficient PC (BRCA2-ve), 
BRCA2 deficient PC (BRCA2+ve) typically presents at 
a younger age, is more poorly differentiated and aggres-
sive, and is associated with worse survival outcomes than 
non-BRCA2 associated PC. Evidence for the more adverse 
clinical presentation comes from multiple studies. Carter 
et al30 provided evidence that germline BRCA2 carriers are 
more likely to be reclassified from Gleason score (GS) 3+3 
at diagnosis to GS ≥4+3 (4.1% (BRCA2+ve) vs 0.7% 
(BRCA2-ve), (p=0.01)) versus GS 3+4 (2.1% (BRCA2 
+ve) vs 0.6% (BRCA2-ve), (p=0.03)). They indicated 
that BRCA2 carriers have more unfavourable prognostic 
indicators and a greater chance of progression from loca-
lised PC to metastatic castration-resistant PC (mCRPC) 
(which has a median survival rate 18–36 months).
A systematic review by Gleicher et al31 compared PC 
characteristics in both carriers of the BRCA2 germline variant 
(BRCA2+ve) and non-BRCA2 carriers (BRCA2–ve). It was 
found that BRCA2 carriers had higher prostate-specific anti-
gen (PSA) values at diagnosis (p<0.001), a higher proportion 
of PCs with a Gleason score >7 (64% (BRCA2+ve) vs 49% 
(BRCA2-ve), (p<0.001)). In addition, a higher proportion of 
BRCA2+ve tumours have T3/T4 staging (41% (BRCA2+ve) 
vs 29% (BRCA2-ve), (p<0.001)) and higher rates of meta-
static disease at diagnosis (26% (BRCA2+ve) vs 8% 
(BRCA2-ve), (p<0.001)). A study by Wokołorczyk et al32 
found that PC with Gleason scores >8 were more likely in 
men carrying germline BRCA2 variants than in non-carriers 
(75% (BRCA2+ve) vs 22% (BRCA2-ve), (p<0.05)). This 
group stipulated that BRCA2 carriers had a lower mean age 
than non-BRCA2 carriers at the time of their PC diagnosis (57 
years (BRCA2+ve) vs 61 years (BRCA2-ve), p=0.3). In 
a study by Na et al,33 6.07% of men with lethal PC were 
later identified as carriers of pathogenic variants in either 
BRCA1/2 or ATM compared to 1.44% of men with localised 
PC who were carriers of these variants (p=0.0007).
The treatment pathway is therefore more challenging in 
these patients. More potent therapeutic agents are often 
considered rather than more conservative measures with 
active surveillance.7,8,11,28,34–36
Therapeutic Options in BRCA2 Deficient 
Prostate Cancer
Whilst a diagnosis of BRCA2 deficient PC has unfavour-
able prognostic implications, the understanding of the 
underlying molecular defect leading to oncogenesis 
enables a precision medicine approach targeting the DDR 
deficient (DDRd) cancer cells specifically. Poly-ADP 
ribose polymerase (PARP) inhibitors and platinum-based 
chemotherapeutic agents have been identified as particu-
larly valuable treatment options for cancers brought about 
from either somatic or germline variants in DDR genes 
such as BRCA2 and may become standard of care for 
BRCA2 deficient PC patients in the near future.3,17,19,37–39
PARP Inhibitors
One of the main driving forces for oncogenesis in BRCA1/ 
2 deficient cells relates to the disruption of the HR DNA 
repair pathway as a result of biallelic BRCA-loss. In cells 
lacking functional BRCA proteins, HR is impaired, forcing 
the cell to utilise alternative DDR mechanisms such as (i) 
non-homologous end joining (NHEJ) which is less accu-
rate than HR and thus susceptible to errors and (ii) single 
strand (ss) DNA break repair, which is mediated by the 
PARP enzymes, PARP1 and PARP2. Increased depen-
dency on PARP-mediated DDR pathways makes BRCA1/ 
2 deficient cells suitable targets for PARP inhibitor ther-
apy, which would disable PARP1 and PARP2. This forces 
the BRCA deficient cells to try to mend DNA damage in 
the double strand (ds) DNA pathway, which they are 
unable to do due to the BRCA deficiency. Accumulation 
of these ds-DNA breaks increases cell stress, leading to 
cell cycle arrest and cell death via apoptosis. This process 
is known as synthetic lethality.40–43
PARP inhibitors were first investigated as a novel treat-
ment approach for BRCA deficient tumours in 2005 and 
have since proven to be of clinical benefit, with pharma-
ceuticals such as rucaparib and olaparib being approved 
for mCRPC treatment in the US following the results of 
clinical trials such as TOPARP-A, TOPARP-B, PROfound 
and TRITON (Table 1).17,41,44–49 Whilst PARP inhibitor 
use has been documented as a beneficial treatment for 
BRCA deficient mCRPC patients, resistance to these 
drugs is not uncommon and may occur via the acquisition 
of somatic BRCA1/2 variants in the germline allele which 
restore the reading frame (ie BRCA reversion variants) and 
thus the normal functioning of the BRCA protein.50–56 
Case reports by Carneiro et al57 and Ma et al58 have 
identified multiple reversion variants in BRCA2 deficient 
mCRPC patients who developed resistance to olaparib 
treatment. Ma et al58 postulated that the efficacy of 
PARP inhibitor therapy may be reliant on the proportion 
of DDR variants in relation to other variants present within 
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the mutational landscape of the tumour. These reports 
support the utility of circulating tumour DNA (ctDNA) 
analysis monitoring to predict PARP inhibitor resistance in 
mCRPC patients.
Platinum-Based Chemotherapy
In recent years platinum-based chemotherapy has shown 
efficacy in the management of mCRPC associated with 
pathogenic DDR gene variants including BRCA2.37–39 
Platinum-based chemotherapeutic agents work by generat-
ing cross-links between purine bases in DNA which dis-
rupts DNA repair, causing cell death via apoptosis.59
Platinum-based chemotherapy is not routinely used to 
treat mCRPC based on evidence from trials which did not 
show overall survival benefit from standard of care.60 
However, in studies specifically selecting mCRPC patients 
with pathogenic variants in recognised DDR 
genes,37–39,61,62 platinum-based chemotherapy was found 
to ameliorate patient quality of life by decelerating tumour 
progression (Table 2). Reports by Mota et al63 and 
Simmons et al64 (Table 2) highlight the challenge of 
tumour resistance which is especially important in BRCA- 
associated PCs which have already been recognised as 
difficult to treat.
Identification of BRCA2-Deficient 
Prostate Cancer
For our patient in Figure 1, it is important to diagnose that 
he has BRCA2 deficient PC not only for his immediate 
therapeutic management, but also to consider any possible 
heritable predisposition to cancer which may require wider 
cascade screening in the family. Evidence suggesting 
a BRCA2 deficient PC can be acquired from multiple 
sources.
Tumour Phenotype and Somatic 
Pathogenic Variants
As previously discussed, BRCA2 deficient PC often presents 
with poorer prognostic indicators than BRCA proficient PC, 
which may trigger suspicion in the treating clinician.11,18 
Identification of specific biallelic pathogenic variants in 
BRCA2 can be undertaken by next-generation sequencing 
(NGS) of tumour-derived DNA. From February 2021, the 
UK National Genomic Test Directory65 specified that 
somatic gene sequencing of BRCA1 and BRCA2 via NGS 
panel approaches should be undertaken for all PCs, with the 
addition of ATM/CDK12 for metastatic resistant PC cases. 
This standard of care pathway should now be implemented 
by all seven Genomic Laboratory Hubs (GLHs) in the UK, 
reducing inequities in testing pathways which have pre-
viously existed in the UK, and leading to the identification 
of more BRCA2 deficient PC. The identification of a somatic 
pathogenic variant in the BRCA1/2 genes in PC should then 
trigger germline testing for inherited susceptibility according 
to the European Society of Medical Oncology (ESMO) 
guidelines.66 Somatic small panel testing is likely to be 
expanded to a wider number of DDR-related genes through 
gene panel testing, with likely expansion of tumour testing to 
whole genomes in the future. Whole genome somatic NGS 
analysis enables identification of driver mutations driving 
oncogenesis, but in addition enables the identification of 
mutational signatures, and tumour mutational burden, 
which can provide evidence for DDRd driving oncogenesis 
and precision medicine approaches.67
Identification of BRCA2-Related 
Germline Susceptibility to Prostate 
Cancer
Family history is a widely established PC risk factor, with 
some families displaying significant aggregation of PC 
cases; a man with a first-degree relative affected by the 
disease has at least twice the chance of developing this 
condition compared with the general population. Current 
access to BRCA germline genetic testing for PC patients in 
the UK relies on them meeting National Genomic Test 
Directory eligibility criteria R208 (Hereditary Breast and 
Ovarian Cancer) in which family history is an essential 
component.68 Given the primary focus on breast and ovar-
ian cancer in the eligibility criteria and the fact that sys-
tematic family history assessments for those diagnosed 
with PC is not well embedded within clinical pathways, 
men presenting with PC are likely to be underserved with 
respect to germline genetic testing. More robust educa-
tional and training is required in secondary care to ensure 
documentation and collection of family history in men 
with PC to ensure eligible men, such as our proband 
from Figure 1, are identified as having likely genetic 
susceptibility requiring germline testing.
Historically, germline genetic testing of PC patients 
typically involves predictive testing of a known gene in 
patients with a previously identified familial variant increas-
ing cancer risk, or, diagnostic genetic testing of BRCA1/2 in 
the context of a significant family history of breast, ovarian 
and prostate cancer. In our family in Figure 1, diagnostic 
BRCA testing in such pedigrees has often been instigated by 
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a female presenting with breast or ovarian cancer rather 
than a male presenting with PC. To widen our ability to 
identify germline susceptibility to PC, diagnostic gene panel 
testing in PC patients of PC-associated DDR genes (cancer 
susceptibility genes) where a family history suggestive of 
inherited predisposition is absent will detect additional 
germline gene carriers.10
The detection of germline variants can (i) inform 
choice of treatment, (ii) facilitate genetic testing of at- 
risk family members (cascade screening), and (iii) help 
to determine the risk of developing other cancer types 
associated with the genes where variants were 
identified.9,69 It is therefore important that novel strategies 
to improve identification of carriers are being 
implemented.
In our family in Figure 1, the brother of our proband 
has a 50% (1 in 2) chance of also carrying the germline 
BRCA2 pathogenic variant identified in his brother. He 
should be offered a predictive genetic test via clinical 
genetics services to establish his own risk. In this case, 
predictive genetic testing identified that the brother also 
carries the BRCA2 pathogenic variant. This should now 
facilitate entry of the unaffected brother into Screening, 
Prevention and Early Detection (SPED) pathways. The 
sister of the proband with breast cancer is likely to also 
carry the BRCA2 pathogenic variant but should also be 
offered germline predictive testing to clarify. If shown to 
carry the variant she will need discussions about con-
sidering risk reducing bilateral salpingo-oophorectomy 
to reduce her risk of ovarian cancer. The BRCA2 patho-
genic variant is likely to have been inherited from the 
deceased mother who died of ovarian cancer, but cascade 
testing to the maternal uncles and cousins should be 
initiated to identify all at risk individuals. The father 
could be offered predictive testing if no maternal relative 
is identified with the BRCA2 pathogenic variant to 
ensure he is not a carrier, as occasionally, phenocopies 
of cancer diagnoses can mask the side of the family from 
which the variant was inherited.
Barriers to access to SPED for unaffected male BRCA2 
carriers exist across healthcare systems. There is a lack of 
awareness and understanding among male BRCA-carriers 
about their increased risk of developing BRCA-associated 
cancers, which include PC, pancreatic cancer and male 
breast cancer, and this can have a detrimental effect on 
health outcomes.70 Contributing factors to misinformation 
among male BRCA-carriers include (i) limited availability 
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risk of BRCA-associated cancers such as PC and male 
breast cancer,71–73 and (ii) lack of awareness among 
healthcare personnel about men’s inherited cancer predis-
position and available treatment options.74 BRCA1/2 car-
riers are labelled as persons with “Hereditary Breast and 
Ovarian Cancer syndrome”75 which is misleading because 
BRCA1/2 variants increase the risk of other cancers like 
PC, pancreatic cancer and melanoma,76,77 but it also fem-
inizes the condition73,78 leading to stigma within the male 
population.
Improved education and training around identification 
of genetic susceptibility to PC, more streamlined access to 
family history assessment, somatic and germline testing 
for PC patients will all increase identification of indivi-
duals with inherited susceptibility to PC. BRCA-risk infor-
mation specifically adapted for the male population will 
also aid the promotion of more proactive health behaviours 
which in turn enable earlier detection of BRCA-associated 
disease in male BRCA2 carriers.70
Prostate Cancer Screening in 
Unaffected BRCA2 Mutation 
Carriers
Consider now the brother of our proband from Figure 1. 
We have identified he has an increased likelihood of 
developing BRCA2-related PC, and he will want to know 
how this risk may be managed.
Whilst measuring serum concentrations of PSA as 
a means of screening for PC has become common 
practice,79 there are no universally accepted PC screening 
guidelines for men.80 Screening the general population for 
PC using PSA testing is not currently recommended based 
on the results of previous research,81–85 which highlights 
the low specificity of the test.
Data from IMPACT study,80,86 an international multi-
centre PC screening study investigating the utilisation of 
PSA testing in BRCA1/2 carrier males, have suggested that 
PSA testing in these men (who are at increased risk of PC) 
may be of greater clinical benefit than screening the gen-
eral population. Following the completion of the first 
IMPACT study screening round,80 data showed that in 
BRCA2 carriers, the positive predictive value (PPV) of 
biopsy using a PSA threshold of 3.0ng/mL was 48%, 
compared with a lower 33.3% PPV seen in the control 
group. In addition, there was a higher frequency of inter-
mediate-high risk PC detected in BRCA2 carriers with 
PSA values above the 3.0ng/mL threshold for further 
investigation with biopsy. It was also noted the males 
diagnosed with PC below the age of 50 years were all 
BRCA1/2 carriers, and BRCA2 carriers reaching the 3.0ng/ 
mL PSA threshold were significantly younger than their 
counterparts with elevated PSA values. After 3 more years 
of follow-up (4 screening rounds), data analysis reiterated 
the utility of PSA screening in BRCA1/2 carriers described 
previously. When compared with non-BRCA2 carriers, 
BRCA2 carriers had a significantly higher PPV of PSA 
>3.0 ng/mL (31% vs 18%; p=0.025), a higher PC inci-
dence rate per 1000 person years (19.4 vs 12.0; p=0.03), 
a significantly higher frequency of intermediate-high risk 
PC (p=0.011) and were significantly younger at the time of 
PC diagnosis (p=0.044), with the youngest age of onset 
being recorded in a 41-year-old BRCA2 carrier. Overall, 
the results so far from the ongoing IMPACT study further 
substantiate the earlier age of onset and more aggressive 
PC phenotype seen in BRCA2 carriers which has been 
widely reported throughout the literature,11,31–34,36,87 and 
also highlights the efficacy of using PSA testing in this 
patient subgroup.
In another prospective PC screening study, Segal et al88 
sought to investigate the use of PSA testing and multi- 
parametric magnetic resonance imaging (mpMRI) in 188 
male BRCA1/2 carriers. Whilst MRI is widely used for 
breast cancer screening in female BRCA1/2 carriers,89 this 
study was the first to investigate the use of this imagine 
modality for PC screening. Prostate biopsies were offered 
to patients with either an elevated PSA value (PSA >3 ng/ 
mL or elevated age-stratified PSA) and/or a suspicious 
prostatic lesion on mpMRI (PI-RADS ≥3). Of these 
patients, 92 men (85%) underwent a prostate biopsy and 
PC was detected in 16 men (8.5%). Amongst the 92 men 
having a prostate biopsy, 5 different PC screening strate-
gies making use of either (i) PSA testing alone, (ii) 
mpMRI alone or (iii) both PSA testing and mpMRI were 
compared using decision curve analysis. Overall, using 
mpMRI in isolation proved to be the best screening tool, 
picking up 15/16 cancers. Interestingly, in BRCA1/2 car-
riers under the age of 55 years, using mpMRI irrespective 
of PSA value had the most benefit whilst PSA screening 
on its own had zero net benefit. In men older than 55 
years, triaging with PSA testing before offering mpMRI 
had the most benefit.
Based on the results of the IMPACT study80,86 and 
those reported by Segal et al,88 national and/or interna-
tional guidelines for unaffected male BRCA2 carriers, such 
as the brother of our proband in Figure 1, are likely to be 
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published in the near future. This is likely to specify PSA 
testing for male BRCA2 carriers from age 40, with subse-
quent investigations required for individuals with PSA ≥3 
ng/mL.
Conclusion
In this review article, we have discussed the investigation 
and management of BRCA2 deficient PC using a case 
study of a family with a pathogenic germline BRCA2 
variant. We have outlined how BRCA2 deficient PC in 
the proband might present, and management options 
which may have specific relevance for BRCA2 deficient 
PC, such as PARP inhibitors and platinum-based che-
motherapy. We have also highlighted the need to distin-
guish between somatic and germline BRCA2 pathogenic 
variants which may have relevance for cancer predisposi-
tion in other family members, and the screening which can 
be offered to unaffected male BRCA2 carriers. The inclu-
sion of all these facets to BRCA2 deficient PC investiga-
tion and management in our review provides 
a comprehensive overview of the clinical approach to 
a family in which BRCA2 deficient PC is diagnosed. The 
rapid advances in our understanding of the molecular 
pathogenesis of DDRd PC and new treatment paradigms, 
alongside the widened access to both somatic and germline 
genetic analysis for PC patients and their families will 
hopefully enable the robust implementation of high- 
quality evidence based clinical pathways for both the 
management and identification of BRCA deficient PC and 
improved screening, early detection and prevention strate-
gies for individuals at increased genetic risk of PC.
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